Showing 1 - 9 results of 9 for search 'E. A. Pyadushkina', query time: 0.03s Refine Results
  1. 1
    BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS

    BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS by E. A. Pyadushkina

    Published 2017-05-01
    Get full text
    Article
  2. 2
    CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY

    CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY by E. A. Pyadushkina, M. Yu. Frolov

    Published 2016-12-01
    Get full text
    Article
  3. 3
    CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS

    CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS by E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva

    Published 2016-02-01
    Get full text
    Article
  4. 4
    Pharmacoeconomic analysis of thrombopoietin receptor agonists in the treatment of chronic idiopathic thrombocytopenic purpura in adults

    Pharmacoeconomic analysis of thrombopoietin receptor agonists in the treatment of chronic idiopathic thrombocytopenic purpura in adults by E. A. Pyadushkina, M. Yu. Frolov, V. A. Shuvaev, V. A. Rogov

    Published 2018-06-01
    Get full text
    Article
  5. 5
    METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY

    METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY by N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov

    Published 2016-09-01
    Get full text
    Article
  6. 6
    Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system

    Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system by E. A. Pyadushkina, E. V. Derkach, M. Yu. Frolov, V. A. Rogov, A. S. Salasyuk

    Published 2021-02-01
    Get full text
    Article
  7. 7
    Comparative pharmacoeconomic analysis of the use of Bonviva® (ibandronat) to prevent fractures in postmenopausal osteoporosis

    Comparative pharmacoeconomic analysis of the use of Bonviva® (ibandronat) to prevent fractures in postmenopausal osteoporosis by E A Pyadushkina, K V Gerasimova, S V Goryainov, Vitaly Vladimirovich Omelyanovsky, M V Avksentyeva, I S Krysanov

    Published 2012-12-01
    Get full text
    Article
  8. 8
    The use of various genetically engineered biological drugs and selective immunosuppressants within the current provider-payment model of russian diagnosis-related groups

    The use of various genetically engineered biological drugs and selective immunosuppressants within the current provider-payment model of russian diagnosis-related groups by E. V. Derkach, E. A. Pyadushkina, M. V. Avxentyeva, T. V. Boyarskaya, E. E. Yagnenkova, A. S. Mokrova, M. M. Maryanyan

    Published 2020-11-01
    Get full text
    Article
  9. 9
    Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting

    Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting by E. A. Pyadushkina, E. V. Derkach, V. I. Ignatyeva, E. E. Yagnenkova, T. Yu. Klitochenko, T. V. Shelekhova, A. N. Levanov

    Published 2021-07-01
    Get full text
    Article

Search Tools: